The Caisse de dépot et placement du Québec will join the board of cloud data company Druva Inc. as part of an agreement to invest US$100-million in the firm.
The pension plan is the lead investor in Druva’s US$147-million growth round, which also saw participation from existing shareholders, according to a press release.
“The team has developed both a robust subscription-based business model and a solid customer base. With this transaction, we are delighted to support the strong growth of a company whose products are increasingly essential based on the acceleration of enterprise cloud adoption,” said Martin Laguerre, the Caisse’s executive vice-president and head of private equity and capital solutions, in a press release.
Meanwhile, the Caisse also announced the purchase of a 15-per-cent interest in the Indiana Toll Road from majority owner IFM Investors, which retains a 70-per-cent stake in the highway. The 253-kilometre road is operated and maintained under an exclusive concession and lease agreement with the state of Indiana that still has 60 years left to run.
According to a news release on the deal, the Caisse and IFM — an investment group owned by several Australian pension funds — have a history of joint ventures in projects around the world. “ITR is a critical channel for the flow of goods in the United States whose resilience and importance for the logistics industry have been demonstrated in recent months. It will be as essential as ever as the economic recovery takes off,” said Emmanuel Jaclot, the Caisse’s executive vice-president and head of infrastructure, in a press release.
The Caisse also supported long-standing portfolio company Demers Braun Crestline in its acquisition of Medix Specialty Vehicles, a U.S.-based ambulance manufacturer. The terms of the deal weren’t disclosed, but the transaction will boost Demers’ North American workforce to 1,140 workers across 12 production and service centre sites, according to a news release.
In other news, the Public Sector Pension Investment Board was among the investors as Repertoire Immune Medicines completed its US$189-million series B financing round.
The Cambridge, Mass.-based biotech company, which focuses on the development of immune therapies to tackle cancer and other diseases, plans to use the funds to expand its proprietary antigen-discovery platform and boost its manufacturing capabilities.